VERTEX PHARMACEUTICALS INC / MA Finance Lease, Right-of-Use Asset, Amortization
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Finance Lease, Right-of-Use Asset, Amortization of $7.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA finance lease, right-of-use asset, amortization for the quarter ending 2019-12-31 was $13.15M.
- VERTEX PHARMACEUTICALS INC / MA finance lease, right-of-use asset, amortization for the quarter ending 2019-09-30 was $12.22M.
- VERTEX PHARMACEUTICALS INC / MA finance lease, right-of-use asset, amortization for the quarter ending 2019-06-30 was $12.06M.
- VERTEX PHARMACEUTICALS INC / MA finance lease, right-of-use asset, amortization for the quarter ending 2019-03-31 was $12.37M.
- VERTEX PHARMACEUTICALS INC / MA finance lease, right-of-use asset, amortization for fiscal 2025 was $7.20M, a 76.70% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA finance lease, right-of-use asset, amortization for fiscal 2024 was $30.90M, a 27.63% decline from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA finance lease, right-of-use asset, amortization for fiscal 2023 was $42.70M, a 16.27% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA finance lease, right-of-use asset, amortization for fiscal 2022 was $51.00M, a 1.73% decline from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month | Finance Lease, Right-of-Use Asset, Amortization 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $7.20M 10-K · filed 2026-02-13 | ||||
| 2024-12-31 | $30.90M 10-K · filed 2026-02-13 | ||||
| 2023-12-31 | $42.70M 10-K · filed 2026-02-13 | ||||
| 2022-12-31 | $51.00M 10-K · filed 2025-02-13 | ||||
| 2021-12-31 | $51.90M 10-K · filed 2024-02-15 | ||||
| 2020-12-31 | $51.20M 10-K · filed 2023-02-10 | $51.22M 10-K · filed 2021-02-11 | |||
| 2019-12-31 | $13.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $25.37M derived: sum of 2 quarters · filed 2022-02-09 | $37.44M derived: sum of 3 quarters · filed 2022-02-09 | $49.80M 10-K · filed 2022-02-09 | $49.78M 10-K · filed 2020-02-13 |
| 2019-09-30 | $12.22M 10-Q · filed 2019-10-31 | $24.28M derived: sum of 2 quarters · filed 2019-10-31 | $36.65M 10-Q · filed 2019-10-31 | ||
| 2019-06-30 | $12.06M 10-Q · filed 2019-08-01 | $24.43M 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | $12.37M 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |